{"id":"W4387722601","doi":"10.1200/jco.22.02770","title":"Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":277,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Gemcitabine; Erlotinib; Medicine; Internal medicine; Pancreatic cancer; Oncology; Erlotinib Hydrochloride; Hazard ratio; Adverse effect; Placebo; Clinical endpoint; Cancer; Clinical trial; Epidermal growth factor receptor; Pathology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01540728,0.000252589,0.005899948,0.0002613741,0.0000697606,0.000004170778,0.0004016587,0.0003509971,0.0001817552],"category_scores_gemma":[0.01875579,0.0001332063,0.0004402598,0.0009512407,0.001005047,0.0001400037,0.00009896304,0.001360071,9.026128e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007634933,"about_ca_system_score_gemma":0.02908504,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01716525,"about_ca_topic_score_gemma":0.1418853,"domain_scores_codex":[0.9884726,0.002134943,0.00680588,0.0003365628,0.001778138,0.0004718404],"domain_scores_gemma":[0.9822309,0.009442739,0.005642629,0.000294991,0.001934685,0.0004540663],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.4644217,0.004277524,0.5116124,0.0001049266,0.00170475,0.0001132798,0.00009412294,0.0005951812,0.00002962762,0.00004467246,0.003966194,0.01303568],"study_design_scores_gemma":[0.407251,0.02081652,0.5655262,0.0006100405,0.0009508312,0.00001248941,0.00008216611,0.0007339057,0.000009105247,0.00004113269,0.0038607,0.0001059578],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901187,0.0001994052,0.00003250593,0.005150357,0.001837543,0.002058354,0.0001102146,0.000007236924,0.0004856962],"genre_scores_gemma":[0.9958895,0.0009884735,0.0009926478,0.0006696578,0.0009760549,0.0001072985,0.00002377205,0.00002521194,0.0003273209],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.12472,"threshold_uncertainty_score":0.9895096,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2282766189847739,"score_gpt":0.5345134374092202,"score_spread":0.3062368184244463,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}